Skip to main content

Table 2 Treatment characteristics

From: Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

Treatment

N = 159

Chemothrapy regimen-no. (%)

  

   CBDCA + PTX

46

(29)

   CDDP + S-1

46

(29)

   CDDP + VNR

41

(26)

   MVP

14

(9)

   CBDCA + CPT-11

5

(3)

   CDDP + VP-16

4

(2)

   CDDP + VNR + DE-766

3

(2)

RT dose-Gy

  

   Median

60

   Range

52-74

  1. Abbreviations: CBDCA carboplatin, PTX paclitaxel, CDDP cisplatin, VNR vinorelbine, MVP mitomycin, vindesine, and cisplatin, CPT-11 irinotecan, VP-16 etoposide, RT radiation therapy.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us